RVTY vs BIO stock comparison
Revvity vs. Bio-rad Laboratories · data as of November 13, 2026
Revvity (RVTY) has a market value of about $17.2B, Bio-rad Laboratories (BIO) about $9.9B. Over their latest twelve months Revvity had revenue of $2.9B and Bio-rad Laboratories $2.6B.
On our five checks Bio-rad Laboratories scores higher: 2.2 out of 5 (weak) against 1.8 (weak).
By area, the stronger company is Bio-rad Laboratories on value; Bio-rad Laboratories on future growth; Revvity on track record; Revvity on shareholder returns.
Bio-rad Laboratories is cheaper on earnings (P/E 9.7 vs. 68.6).
Revvity leads on 14 of the compared lines and Bio-rad Laboratories on 9.
Side by side
| RVTY | BIO | |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | $9.9B |
| Share price | $154.39 | $366.36 |
| Score | ||
| Overall score (of 5) | 1.8 | 2.2 |
| Value | 0 | 2 |
| Future growth | 1 | 3 |
| Track record | 1 | 0 |
| Financial health | 3 | 3 |
| Shareholder returns | 4 | 3 |
| Valuation | ||
| P/E (TTM) | 68.6 | 9.7 |
| Forward P/E | 26.4 | 34.5 |
| Price / free cash flow | 29.2 | 29.9 |
| Price / sales | 5.9 | 3.8 |
| EV / EBITDA | 24.7 | 92.3 |
| PEG | — | — |
| DCF value vs. price | −56% | −62% |
| Business | ||
| Revenue | $2.9B | $2.6B |
| Net income | $253M | $1.0B |
| Free cash flow | $590M | $329M |
| Net margin | 8.6% | 39.5% |
| Gross margin (5-yr avg.) | 61.8% | 54.2% |
| ROIC (5-yr avg.) | 4.1% | 2.4% |
| Growth | ||
| Revenue growth (1 yr) | 3.7% | 0.7% |
| Revenue growth (5 yrs, per year) | -5.5% | 0.3% |
| EPS growth (5 yrs, per year) | -20.4% | -26.1% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$2.2B | $301M |
| Dividend yield | 0.18% | None |
| Shareholder yield | 4.9% | 3.0% |
| Analysts | ||
| Upside to average target | +11% | −3% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: RVTY TTM to October 4, 2026, BIO TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Revvity or Bio-rad Laboratories?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Bio-rad Laboratories scores 2.2 out of 5 and Revvity 1.8; the table shows where each one is stronger.
Is Revvity cheaper than Bio-rad Laboratories?
On trailing earnings, Bio-rad Laboratories trades at a P/E of 9.7 and Revvity at 68.6, so Bio-rad Laboratories is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Revvity or Bio-rad Laboratories?
Over five years Bio-rad Laboratories grew revenue about 0.3% a year and Revvity about -5.5% a year.
Which pays a higher dividend?
Revvity yields 0.18% and Bio-rad Laboratories nothing (no dividend).
Full Revvity analysis → Full Bio-rad Laboratories analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.